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S_ry Temozomide, an imida ane dervatie, was given to 18 patients with low-grade non-
Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to
1000mgm-2 over 5 days (Le. 20OmgMr2day'1) if no sgifiant myclosuppression was noted at day 22 of
the 28 day cyce. Fifty-six teatment cyces were givn to 18 patients. The drug was wl tolerated. Only one
partil tumour response was documented. The paets wre heavily preated but had cemoreonsive
disease as shown by a response rate of 69'!. among 13 patients who went on to receive altenative cytotoxic
We conclude that temozolomide given in this sheduk is inacve in previously treated low-grade
NHL.
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Low-grade non-Hodgin's lymphoma (NHL) is sensitive to a
wide variety of treatments, including radiation, single-agent
alkylating therapy, combination chemotherapy and inter-
ferons. Although tumour responses are common even in
recurrent disease, low-grade NHL follows a chronic relapsing
pattern of disease. The majority of patients die from their
disee, with a median survival of 6-10 years (Horning,
1994). There is therefore a continuing need for novel
treatments for low-grade NHL.
Temozolomide is an imidamtetrazine derivative with
broad-spectrum anti-tumour activity in experimental models
(Stevens et al., 1987; Stevens and Newlands, 1993). It is an
analogue of mitozolomide with less toxicity in precinical
studies, but myelosuppression remains dose limiting (New-
lands et al., 1992). It has excellent oral bioavailability. In
preclinical stdies, its activity was schedule dependent. In
phase I and II studies it has shown promising actity against
metastatic melanoma and primary brain tumours when
adminitered daily for five consecutive days every 4 weeks
(Newlands et al., 1992; O'Reilly et al., 1993). Responses were
also obtained in two patients with mycosis fungoides. We
therefore tested temozolomide for activity in low-grade NHL
using the 5 day schdule.
PradeU a~nd
Patients with histologically confirmed low-grade NHL (Kiel
claition) and measurable or evaluable lesions with
documented progresson in the previous 2 months were
eligible for the study. Patients with eukaemic progression
(ymphocytosis> 10'1'), other prior malignant disease or
uncontrolled medical conditions were excluded. No chemo-
therapy or radiotherapy was permitted in the 4 weeks before
study entry, and patients were required to have a life expec-
tancy of more than 3 months. Systemic steroids were not
permitted during the study. Written informed consent was
obtaied. Patients underwent standard staging investigations,
inluding bone marrow biopsy, before starting treatment.
Temozolomide was supplied in gelatin capsules by the
CRC Formulation Unit, Department of Pharmacy, Univer-
sity of Strathclyde, Glasgow, UK. Treatment was given by
mouth at a dose of 750 mgm-2 divided over five consecutive
days (i.e. 150mgm-2 day l). If no signiint myelosuppres-
sion was noted at day 22, subsequent cycles were given at
1000mgm2 over 5 days (i.e. 200mgm2day-'), repeated
every 28 days. Drug administration was postponed by 1 week
if there was not full haematological reoovery (WBC>3 x
109l1-, platelets>100 x 1091-') from the previous cycle.
Dose reductions were made to 75% for common toxicity
criteria (CTC) grade 3 leucopenia or grade 2 or 3 throm-
bocytopenia, and to 50% for grade 4 lucopenia or throm-
bocytopenia
The study was approved by the Protocol Review Commit-
tee of the Cancer Research Campaign, and by local medical
ethics committees. Study monitoring and analysis were per-
formed by the Cancer Research Campaign Phase I/H Data
Centre.
RcseIs
Patient characteristics
Eighteen patients were enrolled in the study, all of whom
were eligible and have been included in this analysis. Their
status at entry is shown in Table I. They were typical of
patients with indolent low-grade NHL a median (range) of
67.5 (15-168) months from diagnosis. Seven had been
previously treated by surgery (usually splenectomy), six by
radiotherapy and five with a biological agent. All had
recived prior chemotherapy, with a median (range) of three
(1-7) regm. All the patents with lymph node involve-
ment, two were bone marrow positive, three had lung meta-
Table I Patient characteristics
Number 18
Gender Ten male, eight fen
Median age (range) (years) 64 (33-78)
WHO performance status Five grade 0, 13 gra
Histogy
Follicular centroblastic/centrocytic 12
Lymphocytic 2
Ly 2
Centrocytic1
Nrolyinphocyt
Median time from dia s (range) (months) 67.5 (15-168)
Median number of prior chemotherapies (range) 3 (1-7)
male
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stases, two had liver metastases and two had pleural
effusions.
Temozolomide treatment and toxicity
Fifty-six cycles of temozolomide treatment were given to the
18 patients (median three cycles, range 1-6). Adverse events
were scored using the CTC. In three cycles the dose was
reduced or delayed because of thrombocytopenia, in one
because of leucopenia and in one because of vomiting.
Haematological adverse events are shown in Table II. There
were ten reports of infection in nine patients, but none of
these required hospital admission. The most commonly
reported side-effects of temozolomide treatment were nausea
and vomiting, with 26 reports ofvomiting in 16 patients, five
of grade 3. Sickness was usually readily controlled with
antimeics, including 5-HT3 antagonists. There were seven
reports of stomatitis in two patients, two of gade 3. There
were 17 reports of constipation in seven patients, two of
grade 3, at least half of which were associated with opiate
analgescs. Only two serious adverse events were reported,
one episode of hypercacaemia and one of ureteric obstruc-
tion. Neither was attributed to temozolomide.
Responses
One partl tumour response was documented, four patients
had stable disease and 13 had progressive disease. The res-
ponding patient had a 14 year history of follicular
centroblastic/centrocytic NHL. She had an immediate and
sustained reduction in palpable bmphadenopathy and a
greater than 50% reduction in the marker lymph node
masses in the abdomen and chest on CT scan at teatment
cycle 4. Temozolomide treatment was discontinued after six
cycles because ther had been little symptomatic improve-
ment in the patient and no further response. Interetingly, 13
patients went on to receive further cytotoxic chemotherapy.
Of these, nine achieved a partial response and two had
progressve disease on their next treatment regimen. Seven of
nine patients treated with an anthracycline-containing
reipmen achieved a response, and two offour patients treated
without anthracyclines. The remaining patients were observed
off treatment (4) or received prednisolone alone (1).
Tabe HI Haematological adverse events dung temozolomde
treatment, shown as worst CTC grade for 56 treatment cycles in 18
patients
CTCgrade
0 1 2 3 4
Leucocytes 35 17 3 1 0
Neutrophils 45 4 5 2 0
Platelets 27 21 4 4 0
Haemoglobin 28 21 7 0 0
This phase II study indiates that temozolomide given in this
schedule is iactive in low-grade NHL (96% certainty that
the response rate is <20%). The patient population studied
was very heavily pretreated, with a median of three prior
chemotherapy . Many phase H trials are criticised
for incling only end-stage patients with chemoresistant
diseas. It is therefore particulay intresting to note that a
response rate of 69% was seen to subsequent cytotoxic
regimens in the 13 patients who roceived them. Thus,
temozolomide failed to elicit responses in these patients with
chemoresponsive disease. Furthermore, in the one patient
who achieved a documented partial response to treatment,
temozolomide was discontinued because there had been little
clinical benefit.
Temozolomide was well tolerated in this study. In previous
studies, myelosuppression occurred in approximately 5% of
patients treated at a dosage level of750mgm-2 (Newlands et
al., 1992; O'Reilly et al., 1993). Here, dose escalation was
safely achieved, with no patient expericing grade 4
haematological toxicity or neutropenic sepsis. Nausea was
controllEd with simple antiemetics.
Temozolomide has shown promising activity in malignant
melanoma and primary brain tumours. It warrants further
investigation in these and other tumour types.
T'he phase I and nstudies of temozolkmide wer performed under
the auspices of the Cancer Research Campaign Phase I/II Clinical
Trial Committee.
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